Healthcare Services

An Important Factor Driving the Oncolytic Adenovirus Market Is the Surge In Cancer Diagnoses Drives Breakthroughs In Precision Treatment Technologies

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Oncolytic Adenovirus Market Between 2026 And 2030?

The oncolytic adenovirus market has demonstrated significant growth in its size over recent years. It is projected to expand from $132.49 billion in 2025 to $143.57 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. This historical expansion can be linked to the emergence of first-generation adenovirus-based therapies, the increasing occurrence of melanoma and prostate cancer, a surge in investment in oncolytic virus research, prompt adoption by cancer research institutes, and strengthening collaborations between biotechnology and academic institutions.

The oncolytic adenovirus market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $195.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this anticipated growth include an escalating demand for engineered adenovirus therapies, their expanding use in treating breast, ovarian, and lung cancers, increased involvement from biotechnology firms, a surge in funding directed towards clinical trials and research and development, and the broadening capacities of hospitals and research institutions in gene therapy. Key trends expected during the forecast timeframe encompass the increasing integration of AI and big data in oncolytic virus research, wider application of genomics and precision medicine in virus engineering, a rise in the utilization of digital platforms for overseeing clinical trials, enhanced automation in the production and quality control of viral agents, and improved IoT-enabled systems for monitoring virus storage and distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Major Drivers Are Influencing Demand In The Oncolytic Adenovirus Market?

The rising occurrence of cancer is projected to fuel the expansion of the oncolytic adenovirus market in the future. Cancer, defined by the unchecked proliferation of cells and their dissemination throughout the body, presents a significant health challenge. This surge in cancer cases stems from an aging global demographic, various lifestyle influences, environmental exposures, inherited genetic susceptibilities, and enhanced diagnostic capabilities. Oncolytic adenovirus offers a promising therapeutic strategy by specifically targeting and eradicating cancer cells, thereby addressing the growing incidence of the disease. For example, data from May 2024 released by the National Cancer Institute (NCI), a US government agency, indicated nearly 20 million new cancer cases and 9.7 million deaths globally, with forecasts for 2040 suggesting an increase to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australian government body, reported that 1.8% of Australians were affected by cancer, with males (2.1%) showing a slightly higher prevalence than females (1.6%), particularly among individuals aged 75 and over. Consequently, the expanding prevalence of cancer is a key factor propelling the oncolytic adenovirus market’s growth.

Which Market Segments Are Examined In The Oncolytic Adenovirus Market Study?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

How Are Trends Transforming The Oncolytic Adenovirus Market Landscape?

Leading entities within the oncolytic adenovirus sector are prioritizing integrated therapeutic approaches, exemplified by VCN-01, where oncolytic virotherapy is paired with chemotherapy to achieve better tumor targeting and elevate treatment effectiveness. VCN-01 is an oncolytic adenovirus designed for selective infection and destruction of malignant cells, concurrently boosting the efficacy of chemotherapy. A notable example occurred in May 2024, when Theriva Biologics, a US-based clinical-stage immuno-oncology company, revealed that the U.S. Food and Drug Administration (FDA) had bestowed Fast Track Designation (FTD) upon its lead candidate, VCN-01. The FTD is applicable to VCN-01 when employed synergistically with gemcitabine and nab-paclitaxel for addressing metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that specifically aims for and multiplies inside tumor cells, assisting in the degradation of the tumor stroma, which represents a significant impediment to successful cancer therapy.

Who Are The Primary Competitors In The Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Read the full oncolytic adenovirus market report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Oncolytic Adenovirus Market?

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncolytic Adenovirus Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company

Companion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795